Third European Medicines Agency (EMA) and MedTech Europe bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, 2 July 2024

General conditions of purchase orders

Timetable: Type II variation and worksharing application monthly assessment

Shortage of Actilyse (alteplase) and Actilyse Cathflo (alteplase)

Shortage of Metalyse (tenecteplase)

Human medicines European public assessment report (EPAR): Vanflyta, quizartinib, Date of authorisation: 06/11/2023, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Pioglitazone Accord, pioglitazone, Date of authorisation: 21/03/2012, Revision: 9, Status: Authorised

ICH guideline E11A on pediatric extrapolation Step 5

Seventh European Medicines Agency - Medicines for Europe annual bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, from 29 May 2024, 14:00 (CEST) to 29 May 2024, 16:00 (CEST)

Questions and answers relating to Grant Procedure no. EMA/GRANT/2024/02/IA - Medicines regulatory systems strengthening in Sub-Saharan Africa